AMRX Panoramica delle azioni Amneal Pharmaceuticals, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e distribuisce in tutto il mondo farmaci generici, iniettabili, biosimilari e specialità farmaceutiche di marca. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Amneal Pharmaceuticals, Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Amneal Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione US$7.83 Massimo di 52 settimane US$9.48 Minimo di 52 settimane US$5.01 Beta 1.1 Variazione di 1 mese -5.32% Variazione a 3 mesi -10.00% Variazione di 1 anno 29.00% Variazione a 3 anni 61.44% Variazione a 5 anni 65.54% Variazione dall'IPO -47.83%
Notizie e aggiornamenti recenti
Independent Director recently sold US$334k worth of stock Nov 26
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Consensus EPS estimates fall by 17% Nov 21
Senior VP recently sold US$376k worth of stock Nov 20
Senior VP notifies of intention to sell stock Nov 17
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price Nov 10 Vedi altri aggiornamenti
Independent Director recently sold US$334k worth of stock Nov 26
Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist Nov 22
Consensus EPS estimates fall by 17% Nov 21
Senior VP recently sold US$376k worth of stock Nov 20
Senior VP notifies of intention to sell stock Nov 17
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price Nov 10
Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023) Nov 10
Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024 Nov 08
New major risk - Shareholder dilution Nov 07
Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 09
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials Aug 20
Insider recently sold US$775k worth of stock Aug 18
Insider notifies of intention to sell stock Aug 16
Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023) Aug 11
Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024 Aug 09
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules Aug 08
Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags Jul 30
Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 12
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success Jul 10
Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant Jul 10
Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar Jul 03
Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies Jun 06
Independent Director recently sold US$256k worth of stock May 21
Independent Director notifies of intention to sell stock May 19
Price target increased by 13% to US$8.25 May 06
New major risk - Negative shareholders equity May 04
First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) May 04
Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose Apr 25
Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA) Apr 19
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price Apr 15
Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024 Apr 11
Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024 Mar 23
Price target increased by 7.3% to US$7.31 Mar 21
Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet? Mar 19
Insider exercised options and sold US$332k worth of stock Mar 06
Full year 2023 earnings: EPS misses analyst expectations Mar 04
Consensus EPS estimates fall by 17% Mar 03
Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024 Mar 01
Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024 Feb 01 Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry Dec 28
Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company Dec 10
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt? Nov 28
New major risk - Financial position Nov 09
Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023 Oct 24
Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 06
Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt Sep 24 Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection
Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease Aug 25
Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt? Aug 08
Price target increased by 50% to US$5.25 Aug 07
Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023 Aug 05
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics Jul 27
Amneal Pharmaceuticals Could Have An Upbeat Q2 Jul 10
Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023 Jul 07
Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter Jul 04
Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable Jun 15
Consensus EPS estimates fall by 25% May 26
Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States May 17
Price target decreased by 18% to US$3.50 May 09
Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023 May 06
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 06
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively Apr 18
Price target decreased by 18% to US$4.20 Mar 10
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 03
Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023 Feb 01
Amneal Pharmaceuticals: Risk Still Persists Jan 23
Amneal Pharma reaffirms 2022 guidance Jan 10
Amneal joins hands with Orion to commercialize generic products in Europe and more countries Jan 04
Insufficient new directors Jan 01
Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval Dec 21
Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load Dec 20
Amneal Pharmaceuticals large shareholder TPG cuts stake Dec 14
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States Nov 23
Price target decreased to US$5.10 Nov 16
Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease Nov 12
FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203 Nov 11
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 05 Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022
Amneal Pharmaceuticals Q3 2022 Earnings Preview Nov 03
Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection Nov 03
Amneal Pharmaceuticals, Inc. Announces Management Changes Nov 01
Amneal Pharmaceuticals: A Small 'Thumbs Up' Oct 28
Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022 Oct 07
Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS Oct 04
Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty Sep 07
Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease Sep 01
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet Sep 01
Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment Aug 31
Consensus forecasts updated Aug 22
Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose Aug 12
Price target decreased to US$5.80 Aug 08
Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022 Aug 06 Rendimenti per gli azionisti AMRX US Pharmaceuticals US Mercato 7D 0.5% -1.9% -1.1% 1Y 29.0% 6.5% 22.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: AMRX ha superato il US Pharmaceuticals che ha restituito 6.5 % nell'ultimo anno.
Rendimento vs Mercato: AMRX ha superato il mercato US che ha restituito 22.4 % nell'ultimo anno.
Volatilità dei prezzi Is AMRX's price volatile compared to industry and market? AMRX volatility AMRX Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.6% 10% least volatile stocks in US Market 3.1%
Prezzo delle azioni stabile: AMRX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di AMRX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2002 7,850 Chirag Patel amneal.com
Amneal Pharmaceuticals, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e distribuisce in tutto il mondo farmaci generici, iniettabili, biosimilari e specialità farmaceutiche di marca. L'azienda opera attraverso tre segmenti: Generici, Specialità e AvKARE. Il segmento Generics offre prodotti orali solidi, in polvere, liquidi, iniettabili sterili, spray nasali, inalatori e respiratori, biosimilari, oftalmici, film, cerotti transdermici e prodotti topici a rilascio immediato ed esteso.
Mostra di più Amneal Pharmaceuticals, Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Amneal Pharmaceuticals con la sua capitalizzazione di mercato? AMRX statistiche fondamentali Capitalizzazione di mercato US$2.42b Guadagni(TTM ) -US$184.45m Ricavi(TTM ) US$2.68b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) AMRX Conto economico (TTM ) Ricavi US$2.68b Costo del fatturato US$1.70b Profitto lordo US$979.05m Altre spese US$1.16b Guadagni -US$184.45m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.60 Margine lordo 36.53% Margine di profitto netto -6.88% Rapporto debito/patrimonio netto -7,524.6%
Come si è comportato AMRX nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/30 10:32 Prezzo dell'azione a fine giornata 2024/12/30 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Amneal Pharmaceuticals, Inc. è coperta da 20 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Balaji Prasad Barclays Balaji Prasad Barclays Gary Nachman BMO Capital Markets Equity Research
Mostra 17 altri analisti 
